Lucid Diagnostics Inc. (NASDAQ:LUCD) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Lucid Diagnostics Inc. (NASDAQ:LUCD) have been assigned an average rating of “Moderate Buy” from the five ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $4.1250.

A number of equities research analysts have recently commented on the company. Ascendiant Capital Markets increased their price objective on Lucid Diagnostics from $8.25 to $9.00 and gave the company a “buy” rating in a research report on Thursday, April 9th. Maxim Group cut their price objective on Lucid Diagnostics from $3.00 to $2.00 and set a “buy” rating for the company in a research report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Lucid Diagnostics in a report on Wednesday, May 6th. Wall Street Zen lowered Lucid Diagnostics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Needham & Company LLC restated a “buy” rating and issued a $3.00 target price on shares of Lucid Diagnostics in a report on Thursday, March 26th.

Lucid Diagnostics Stock Performance

Shares of NASDAQ:LUCD opened at $0.99 on Wednesday. Lucid Diagnostics has a one year low of $0.95 and a one year high of $1.70. The stock has a fifty day moving average of $1.20 and a 200-day moving average of $1.18. The company has a market capitalization of $201.26 million, a PE ratio of -2.11 and a beta of 1.10.

Lucid Diagnostics (NASDAQ:LUCD) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The firm had revenue of $1.26 million during the quarter, compared to the consensus estimate of $1.38 million. As a group, research analysts forecast that Lucid Diagnostics will post -0.22 EPS for the current fiscal year.

Institutional Trading of Lucid Diagnostics

A number of hedge funds have recently modified their holdings of the business. XML Financial LLC lifted its holdings in shares of Lucid Diagnostics by 24.8% in the first quarter. XML Financial LLC now owns 223,195 shares of the company’s stock valued at $257,000 after purchasing an additional 44,400 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Lucid Diagnostics in the fourth quarter valued at $246,000. Millennium Management LLC purchased a new stake in shares of Lucid Diagnostics in the fourth quarter valued at $168,000. Abel Hall LLC purchased a new stake in shares of Lucid Diagnostics in the fourth quarter valued at $33,000. Finally, Squarepoint Ops LLC lifted its holdings in shares of Lucid Diagnostics by 1,871.7% in the fourth quarter. Squarepoint Ops LLC now owns 342,883 shares of the company’s stock valued at $374,000 after purchasing an additional 325,493 shares in the last quarter. Hedge funds and other institutional investors own 74.01% of the company’s stock.

About Lucid Diagnostics

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.